Chemomab Therapeutics Ltd. CMMB
We take great care to ensure that the data presented and summarized in this overview for Chemomab Therapeutics Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CMMB
View all-
Orbimed Advisors LLC San Diego, CA2.24MShares$2.4 Million0.04% of portfolio
-
Ikarian Capital, LLC Dallas, TX213KShares$228,3290.02% of portfolio
-
Two Sigma Investments, LP New York, NY40KShares$42,7930.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny37.8KShares$40,4460.0% of portfolio
-
Kestra Private Wealth Services, LLC31.2KShares$33,4270.0% of portfolio
-
Boothbay Fund Management, LLC New York, NY26.5KShares$28,3860.0% of portfolio
-
Two Sigma Securities, LLC New York, NY26.2KShares$28,0170.0% of portfolio
-
Rhumbline Advisers Boston, MA18.6KShares$19,9300.0% of portfolio
-
Geode Capital Management, LLC Boston, MA11.7KShares$12,5580.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA11.5KShares$12,2800.0% of portfolio
Latest Institutional Activity in CMMB
Top Purchases
Top Sells
About CMMB
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Insider Transactions at CMMB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 03
2023
|
Orbi Med Israel Gp Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
336,900
-6.69%
|
$1,010,700
$3.93 P/Share
|
|
Jan 03
2023
|
George Adi Mor Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
6,100
-2.37%
|
$30,500
$5.03 P/Share
|
|
Jan 03
2023
|
George Adi Mor Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,700
-2.37%
|
$38,500
$5.03 P/Share
|
|
Nov 16
2022
|
Neil Harris Cohen Director |
SELL
Open market or private sale
|
Direct |
2,409
-19.41%
|
$4,818
$2.0 P/Share
|
|
Nov 16
2022
|
George Adi Mor Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
257,248
-50.0%
|
$514,496
$2.08 P/Share
|
|
Nov 16
2022
|
George Adi Mor Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
324,775
-50.0%
|
$649,550
$2.08 P/Share
|
|
May 24
2022
|
Joel Michael Maryles Director |
BUY
Open market or private purchase
|
Direct |
433
+12.24%
|
$866
$2.83 P/Share
|
|
May 18
2022
|
Neil Harris Cohen Director |
BUY
Open market or private purchase
|
Direct |
2,000
+13.88%
|
$6,000
$3.19 P/Share
|
|
Mar 18
2022
|
Joel Michael Maryles Director |
BUY
Open market or private purchase
|
Direct |
1,000
+41.67%
|
$4,000
$4.34 P/Share
|
|
Mar 16
2022
|
Donald Marvin Executive VP, CFO & COO |
BUY
Open market or private purchase
|
Direct |
500
+11.81%
|
$1,500
$3.28 P/Share
|
|
Mar 14
2022
|
Donald Marvin Executive VP, CFO & COO |
BUY
Open market or private purchase
|
Direct |
1,250
+26.86%
|
$5,000
$4.04 P/Share
|
|
Mar 14
2022
|
Neil Harris Cohen Director |
BUY
Open market or private purchase
|
Direct |
6,000
+19.71%
|
$24,000
$4.35 P/Share
|
|
Mar 14
2022
|
Dale R Pfost Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+35.94%
|
$7,500
$3.98 P/Share
|
|
Mar 11
2022
|
Nissim Darvish Director |
BUY
Open market or private purchase
|
Direct |
1,200
+50.0%
|
$4,800
$4.28 P/Share
|
|
Dec 06
2021
|
Neil Harris Cohen Director |
BUY
Open market or private purchase
|
Direct |
2,000
+31.21%
|
$14,000
$7.43 P/Share
|
|
Mar 16
2021
|
Neil Harris Cohen Director |
BUY
Open market or private purchase
|
Direct |
2,409
+50.0%
|
$98,769
$41.51 P/Share
|
|
Mar 16
2021
|
Peter Thiel > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
230,536
+17.22%
|
-
|
|
Mar 16
2021
|
Orbi Med Israel Gp Ltd. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
288,170
+10.05%
|
$4,898,890
$17.35 P/Share
|